Billionaire Johann Rupert's Remgro just won approval to take full control of 50 South African hospitals

South Africa's Competition Tribunal has approved Johann Rupert's Remgro to take full ownership of Mediclinic Southern Africa, clearing the final major domestic regulatory hurdle for a $950 million deal that hands the Rupert-chaired investment group control of 50 private hospitals, 15 day-case clinics, six sub-acute facilities and six mental health centres across the country.

The approval, confirmed on June 11, 2026, advances a transaction that Remgro announced on March 31, 2026, in which it agreed to restructure its joint ownership of Mediclinic International with Investment Holding Limited, a subsidiary of the Mediterranean Shipping Company. Under the terms of the deal, IHL takes full ownership of Hirslanden, Mediclinic's Swiss private hospital group, while Remgro acquires 100 percent of Mediclinic Southern Africa, which includes the Intercare group of companies and ER24 EMS. The two components are executed simultaneously at an equal consideration of $950 million each, valued at approximately R16.2 billion at the time of announcement.

Remgro and IHL had each held a 50 percent stake in Mediclinic Holdings since June 2023, when Remgro completed its acquisition of the full listed group alongside MSC. The 2026 restructuring dissolves that 50-50 joint venture arrangement and gives each party outright ownership of its home market operations. Remgro and IHL will continue to hold joint interests in the Middle East through the EHH Group and in the United Kingdom through Spire Healthcare.

Mediclinic Southern Africa is the third-largest private healthcare provider in southern Africa by licensed inpatient beds. Its 50 South African hospitals operate 8,991 inpatient beds and employ more than 21,400 people. Three additional private hospitals in Namibia are also included in the MCSA portfolio that Remgro is acquiring. The Intercare group, which operates within the MCSA structure, runs day-case and primary care clinics alongside the main hospital network. ER24 EMS, the emergency medical services operation, is one of South Africa's largest private ambulance and emergency response companies with a national footprint.

The transaction was announced with a long-stop date of September 30, 2027, meaning both parties committed to completing the deal by that deadline. South African competition approval was one of the primary conditions precedent. Swiss regulatory approval in respect of certain tax matters related to the Hirslanden disposal was a separate condition. The Competition Tribunal approval in South Africa removes the domestic hurdle.

Remgro's stated rationale for the deal is concentrated focus. The company has said the transaction will allow it to deepen its relationships with patients, clinicians and regulators in South Africa and to pursue more targeted growth strategies in its core market, rather than managing a geographically dispersed healthcare portfolio across three continents simultaneously. The healthcare division has been one of Remgro's strongest earnings contributors in recent years. Mediclinic's contribution to Remgro's headline earnings grew 57.5 percent to R2.386 billion in the most recent reporting period.

Remgro is Johann Rupert's principal South African investment vehicle. The Rupert family holds all of the unlisted B shares in Remgro, giving the family more than 40 percent of the company's voting rights. Its portfolio spans healthcare, banking, insurance, food and beverage, industrial and media interests. The Mediclinic Southern Africa acquisition is the largest single transaction in Remgro's recent corporate history and represents a significant concentration of the group's healthcare exposure into the South African market at a time when the private healthcare sector faces ongoing debates about affordability, regulation and the National Health Insurance framework.

Rupert, who turned 75 on June 1, 2026, chairs Remgro alongside his role as executive chairman of Compagnie Financière Richemont, the Swiss luxury goods group. His net worth is estimated at approximately $11.5 billion, making him South Africa's wealthiest individual. The Competition Tribunal approval brings Remgro's most consequential healthcare transaction in years a significant step closer to completion.